Visit https://www.peervoice.com/WBG860 to view the entire programme with slides. After completing “Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin”, participants will be able to: Explain the rationale for combining GLP-1 receptor agonists (RAs) and basal insulin for patients with T2DM, based on mechanisms of action and recent guidelines; Evaluate the efficacy of combination therapy of GLP-1 RA and basal insulin on HbA1c, fasting and postprandial glucose, and other key glycaemic control measures; Discuss the most recent safety data for GLP-1 RAs, with a focus on hypoglycaemia, weight gain, and tolerability; Apply clinical data for combination therapy in the management of patients with T2DM in daily practice.